Gain Therapeutics (NASDAQ:GANX) Announces Earnings Results, Beats Expectations By $0.06 EPS

Gain Therapeutics (NASDAQ:GANX) posted its quarterly earnings data on Tuesday. The company reported ($0.07) EPS for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.06, Zacks reports.

Gain Therapeutics Stock Performance

Shares of NASDAQ:GANX traded up $0.01 during mid-day trading on Tuesday, reaching $1.10. 214,793 shares of the company traded hands, compared to its average volume of 710,166. The company’s 50 day moving average price is $1.52 and its 200-day moving average price is $1.83. The company has a debt-to-equity ratio of 0.02, a current ratio of 4.36 and a quick ratio of 4.36. The firm has a market cap of $47.96 million, a PE ratio of -2.20 and a beta of 0.29. Gain Therapeutics has a 52 week low of $0.94 and a 52 week high of $4.34.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on the company. HC Wainwright reissued a “buy” rating and issued a $8.00 target price on shares of Gain Therapeutics in a research report on Monday, October 5th. BTIG Research reissued a “buy” rating and issued a $5.00 price objective on shares of Gain Therapeutics in a report on Monday, October 5th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Gain Therapeutics in a research report on Friday, September 4th. Four investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $7.67.

Gain Therapeutics Company Profile

Gain Therapeutics, Inc is a biotechnology company focused on developing small-molecule therapies for diseases associated with lysosomal dysfunction, including neurodegenerative and rare disorders. The company’s approach is designed to identify compounds that bind to and modulate disease-related proteins, with the goal of restoring their function and addressing underlying disease mechanisms.

Gain Therapeutics’ lead investigational program, GT-02287, is an orally administered, brain-penetrant small molecule being developed for GBA1-associated Parkinson’s disease.